Gregory Becker, MD
Pulmonary Disease · Myrtle Beach, SCNPI 1033107180
Payments from drug & device makers
Across 242 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$767
- Actelion Pharmaceuticals US, Inc.$382
- Sanofi$246
- Insmed, Inc.$228
- Boehringer Ingelheim$205
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,41296%
- Education$1694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 59 | $1,044 |
| AstraZeneca | 40 | $767 |
| Actelion Pharmaceuticals US, Inc. | 26 | $382 |
| Sanofi | 10 | $246 |
| Insmed, Inc. | 9 | $228 |
| Boehringer Ingelheim | 15 | $205 |
| Mylan Specialty L.p. | 8 | $156 |
| Regeneron Healthcare Solutions, Inc. | 6 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $133 |
| Abbott | 6 | $130 |
| AbbVie(2 entities) | 7 | $123 |
| Merck | 6 | $113 |
| Sunovion Pharmaceuticals Inc. | 7 | $88 |
| Astellas Pharma US Inc | 2 | $87 |
| Vifor Pharma, Inc. | 3 | $72 |
| Verona Pharma, Inc. | 3 | $68 |
| Genentech USA, Inc. | 3 | $59 |
| Mallinckrodt Hospital Products Inc. | 2 | $51 |
| Fisher & Paykel Healthcare Inc | 2 | $49 |
| Pfizer | 2 | $45 |
| Grifols USA, LLC | 2 | $44 |
| Philips North America LLC | 2 | $41 |
| Amgen | 2 | $41 |
| Shire North American Group Inc | 2 | $35 |
| Johnson & Johnson(2 entities) | 2 | $35 |
| Bayer | 2 | $31 |
| Baxter Healthcare | 1 | $23 |
| Viatris Specialty LLC | 1 | $19 |
| Electromed, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| United Therapeutics Corporation | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $14 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$113
How this compares
$4,581 in reported general payments places this provider in the 55th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 235 | $211,829 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $42,261 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $39,241 |
| Spiriva RespimatTiotropium Bromide | 26 | $28,295 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $17,005 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 67 | $15,444 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $10,240 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 260 | $6,972 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,413 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,278 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $6,074 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,495 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $1,975 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,689 |
| Montelukast Sodium | 101 | $848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,044 | $260,368313 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $767 | $45,65373 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $205 | $45,30053 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Myrtle Beach
- Adam BostickMyrtle Beach$38K
- Alan CohenMyrtle Beach$12K
- Charles FogartySpartanburg$18.7M
- Gregory FeldmanColumbia$15.1M
- Farhan SiddiquiSpartanburg$8.6M
- Joseph BosciaSpartanburg$7.9M
- Charles ThompsonAnderson$7.7M
- David ErbSpartanburg$7.5M
- Richard BoganColumbia$4.8M
- Patrick FlumeCharleston$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.